A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
Open Access
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 71 (1) , 97-101
- https://doi.org/10.1038/bjc.1995.19
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumideEuropean Journal Of Cancer, 1992
- SMS 201–995 treatment and advanced intestinal cancer: a pilot studyAlimentary Pharmacology & Therapeutics, 1987
- Treatment of Inoperable Glucagonoma with the Long-Acting Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1986
- Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administrationActa Endocrinologica, 1986
- Autocrine and paracrine growth regulation of human breast cancerJournal of Steroid Biochemistry, 1986
- SomatostatinNew England Journal of Medicine, 1983
- Simian Sarcoma Virus onc Gene, v- sis , Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth FactorScience, 1983
- Evidence for an intracellular somatostatin receptor in pancreas: A comparative study with reference to gastric mucosaBiochemical and Biophysical Research Communications, 1982
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Growth responses of rat stomach cancer cells to gastro‐entero‐pancreatic hormonesInternational Journal of Cancer, 1982